F2 and hemorrhage: One randomized phase IIIb, multicenter, open-label, non-inferiority trial, in 202 patients with VKA-associated hemorrhage (only 24 ICH-patients), showed that abnormal coagulation was more rapidly reversed by vitamin K and 4-factor PCC (containing coagulation factors II, VII, IX, X) applied using staggered dosing (INR 2–4: 25 IU/kg BW, INR 4–6: 35 IU/kg BW, INR > 6: 50 IU/kg BW) compared to fresh frozen plasma (FFP dosing, INR 2–4: 10 ml/kg, INR 4–6: 12 ml/kg, INR > 6: 15 ml/kg), i.e., INR ≤ 1.3, achieved by PCC + vitamin K in 62.2% versus FFP + vitamin K in 9.6% [26].